Afuco™ Anti-IL12+IL23 ADCC Therapeutic Antibody (Briakinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-103 |
| Pricing | Inquiry |
| Host | Human |
| Target | IL12+IL23 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |